La Dra. María López Lluva analiza los resultados del estudio publicado en ACC Congress 2020.

1. The PARTNER 3 Trial María Thiscal López Lluva

2. The PARTNER 3 Trial María Thiscal López Lluva

3. The PARTNER 3 Trial María Thiscal López Lluva

4. The PARTNER 3 Trial María Thiscal López Lluva

5. The PARTNER 3 Trial María Thiscal López Lluva

6. The PARTNER 3 Trial María Thiscal López Lluva
Year 1 to 2

7. The PARTNER 3 Trial María Thiscal López Lluva
Year 1 to 2

8. The PARTNER 3 Trial María Thiscal López Lluva
Year 1 to 2

9. The PARTNER 3 Trial María Thiscal López Lluva

10. The PARTNER 3 Trial María Thiscal López Lluva

11. The PARTNER 3 Trial María Thiscal López Lluva

12. The PARTNER 3 Trial María Thiscal López Lluva
CONCLUSIONS
In a defined population of severe symptomatic AS patients who were at low surgical risk, TAVR (using the SAPIEN 3
valve) compared to surgery at 2 years demonstrated:
1. Reduced primary endpoint events (⇣ 37% in death, stroke or CV rehospitalization), BUT...
- More death and stroke events in TAVR patients from 1 to 2 years; but no significant differences at 2 years
- Reduced CV rehospitalizations favoring TAVR
2. Increased valve thrombosis events in TAVR patients, esp. from 1 to 2 years
3. Hemodynamic improvements and frequency of moderate or mild paravalvular regurgitation were unchanged
between 1 and 2 years both TAVR and surgery patients.